DOCSLIB.ORG

Influenza a and B Viruses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influenza a and B Viruses APPENDIX 2 Influenza A and B Viruses (Other Than H5N1) Likelihood of Secondary Transmission: • Characteristic of influenza following exposure to Disease Agents: secretions from infected persons • Influenza A and B viruses At-risk Populations: Disease Agent Characteristics: • Elderly individuals (>65 years) • Family: Orthomyxoviridae; Genera: Influenzavirus A • Infants and pregnant women or Influenzavirus B • Those with a variety of chronic medical conditions • Virion morphology and size: Enveloped, helical • During pandemics, much larger segments of the nucleocapsid, spherical to pleomorphic virions, population are immunologically naïve, and suscep- 80-120 nm in diameter tible to infection. • Nucleic acid: Linear, segmented, negative-sense, single-stranded RNA, ~13.6 kb in length for influenza Vector and Reservoir Involved: A and ~14.6 kb in length for influenza B • Influenza A viruses circulate in birds and mammalian • Physicochemical properties: Virions are sensitive to species, especially pigs, where they undergo antigenic treatment with heat, lipid solvents, nonionic deter- drift and shift with eventual transmission to humans. gents, formaldehyde, oxidizing agents; infectivity • Influenza B infection is confined to humans. reduced after exposure to radiation. Blood Phase: Disease Name: • Animal models of influenza A demonstrate viremia • Influenza after experimental infection. Priority Level: • Virus isolation at autopsy from organs outside the respiratory tract (heart, CNS, kidney, spleen, liver, • Scientific/Epidemiologic evidence regarding blood fetus) is indirect evidence of dissemination during safety: Theoretical natural infection that suggests viremia. • Public perception and/or regulatory concern regard- • Viremia and influenza A “RNA-emia” are described in ing blood safety: Very low a small series of symptomatic patients (who would • Public concern regarding disease agent: Moderate have been disqualified as donors because of Background: symptoms). • A single case report describes influenza A H3N2 • Seasonal epidemics are characteristic of influenza A (Hong Kong) viremia in a naturally infected, asymp- and B. These are primarily in the late fall and winter in tomatic patient, which would be most relevant to temperate climates. concerns about transfusion transmission. • When major changes (antigenic shift) occur in influ- • Experimental human infections have been accompa- enza A antigens, pandemics occur with high attack nied by viremia during the incubation period, but the rates and variable morbidity and mortality. relevance of the high-dose intranasal inoculation (as • Influenza B does not undergo shifts but evolves by opposed to the natural droplet route) has been antigenic drift and is not associated with severe pan- questioned. demics. • Influenza B viremia was detected in 4 of 11 pediatric • Depending on vaccine efficacy and other factors asso- patients 2-4 days after symptom onset. ciated with epidemic activity , epidemics occur annu- ally and pandemics every few decades Survival/Persistence in Blood Products: • Influenza A viruses infect avian species, humans, and • Unknown several other mammalian species (especially swine). Influenza B infects only humans. Transmission by Blood Transfusion: Common Human Exposure Routes: • Never documented • Person-to-person spread primarily via contact with Cases/Frequency in Population: droplets expelled during coughing and sneezing • Virions are present in high titers in nasal secretions • The incidence varies from season to season, but starting about 2-3 days after exposure and just before population attack rates during a pandemic first wave symptoms. can approach 40%. During seasonal epidemics, rates • Preschool and school-age children are major con- of up to 18% are seen (higher in children) and up to tributors to transmission of influenza A viruses. 70% in confined or selected populations. 110S TRANSFUSION Volume 49, August 2009 Supplement APPENDIX 2 • Worldwide prevalence: Up to 10% of weekly mortality • Myalgias, commonly occurring in the back, arm, or attributable to influenza during outbreaks legs • In March-April 2009, a new strain of influenza A H1N1 • Headache, chills, dry cough was isolated in Mexico and then rapidly • Retro-orbital pain, conjunctivitis worldwide. The spread of the virus and disease soon • Fatigue, malaise, anorexia qualified as a level 5 of 6 (the highest indicating a • Tracheobronchitis with rhinorrhea; cough can persist pandemic) using the WHO influenza pandemic for 1 or 2 additional weeks after fever and upper res- definitions. Although formally achieving the existing piratory tract symptoms resolve. WHO criteria for level 6, by community spread of the new H1N1 virus in a second region by the end of May, Severity of Clinical Disease: the WHO did not raise the pandemic alert to level 6 • Symptoms can be severe and associated with until June 11, 2009. This is the organization’s first flu increased hospitalizations during epidemics (1/2900 pandemic declaration in more than 40 years. Raising infected for 1- to 44-year-old group and 1/270 the alert to level 6 does not indicate the disease is infected for those older than 65 years). more fatal or riskier than at level 5, but that it has • During the past four influenza seasons, the peak per- spread to an increasing number of countries. As of centage of patient visits for influenza-like illness June 11, 2009: ranged from 4.0 to 7.6%. ᭺ 74 countries reported 28,774 cases including 144 deaths Mortality: ᭺ 94% of global cases are from the Americas with most from Mexico • Influenza is the cause of excess mortality each year, > ᭺ Cases of disease have been milder than expected especially in persons 65 years (1/2200 infected based on initial reports from cases in Mexico increasing to 1 in 300 infected during a pandemic) • Phylogenetic cluster analyses using the new H1N1 • During pandemics mortality is generally highest at strain and its closest relatives support the fact that the the extremes of age; however, during the 1918 pan- 2009 worldwide H1N1 virus derived from one or mul- demic, there was a mortality peak in young adults. tiple reassortments between influenza A viruses cir- Chronic Carriage: culating in swine in Eurasia and in North America (H1N1, H1N2 and H3N2). •No • Receipt of recent (2005-2009) seasonal influenza vac- cines is unlikely to elicit a protective antibody Treatment Available/Efficacious: response to the novel H1N1 virus • Several antiviral drugs (amantadine and rimantadine) ᭺ 2-fold increase in cross-reactive antibody in and neuraminidase inhibitors (zanamivir, oselta- those aged 18-64 (compared to a 12- to 19-fold mivir) are available that have both prophylactic and for the seasonal H1N1 influenza strain) clinical efficacy, although resistance, including trans- Incubation Period: mission of primary resistant strains, is a major concern. • 1-5 days (longer for influenza B virus) Agent-Specific Screening Question(s): Likelihood of Clinical Disease: • No specific question is in use, but symptomatic • Based on experimental infection, most influenza A donors are excluded by current donor criteria (“Are cases are symptomatic, with high fever in 60-90% of you feeling well and healthy today?”). subjects. • No question is feasible for exposure to influenza A or • Asymptomatic influenza A infection does occur and B during a community outbreak. was documented in 4 of 34 infected prisoners. • While some authorities suggest that influenza B is Laboratory Test(s) Available: milder than A, most believe they closely resemble • No FDA-licensed blood donor screening test exists. each other. • Antemortem diagnosis confirmed by viral isolation, Primary Disease Symptoms: experimental nucleic acid testing for virus-specific RNA, and the less sensitive antigen-detection tests • Abrupt onset of fever of 38-40°C but can reach 41°C • All tests have been validated for sputum/pharyngeal when symptoms first develop; usually continuous but secretions but not for blood or blood fractions. Isola- may come and go; may be lower in older adults than tion may be higher from pharyngeal samples (at a in children and younger adults median of 5.5 days). Volume 49, August 2009 Supplement TRANSFUSION 111S APPENDIX 2 • An RT-PCR assay in minipools for the associated Available from: http://www.cdc.gov/flu/weekly/ influenza A H5N1 subtype has been evaluated in weeklyarchives2004-2005/04-05summary.htm 10,272 blood donor samples. All were negative. 2. Centers for Disease Control and Prevention. Influ- enza outbreak—Madagascar, July-August 2002. Morb Currently Recommended Donor Deferral Period: Mortal Wkly Rep MMWR 2002;51:1016-8. 3. Centers for Disease Control and Prevention. Serum • No FDA Guidance or AABB Standard exists. cross-reactive antibody response to a novel influenza • Prudent practice would be to defer donor until signs A (H1N1) vaccination with seasonal influenza and symptoms are gone. vaccine. Morb Mortal Wkly Rep MMWR 2009;58: Impact on Blood Availability: 521-4. 4. Earhart KC, Beadle C, Miller LK, Pruss MW, Gray GC, • Agent-specific screening question(s): Ledbetter EK, Wallace MR. Outbreak of influenza in ᭺ Symptomatic infection is already a cause for highly vaccinated crew of U.S. Navy ship. Emerg deferral. Infect Dis 2001;7:463-5. ᭺ If there is a concern about asymptomatic viremia 5. Eurosurveillance 2009:14(21). [cited 2009 June]. Avail- and a deferral for contact with influenza is con- able from: http://www.eurosurveillance.org/Public/ sidered during a seasonal outbreak or pandemic, Articles.aspx the impact could be major. 6. Fritz RS, Hayden FG, Calfee
Load more

Recommended publications
  • Influenza Virus Infections in Humans October 2018
    Influenza virus infections in humans October 2018 This note is provided in order to clarify the differences among seasonal influenza, pandemic influenza, and zoonotic or variant influenza. Seasonal influenza Seasonal influenza viruses circulate and cause disease in humans every year. In temperate climates, disease tends to occur seasonally in the winter months, spreading from person-to- person through sneezing, coughing, or touching contaminated surfaces. Seasonal influenza viruses can cause mild to severe illness and even death, particularly in some high-risk individuals. Persons at increased risk for severe disease include pregnant women, the very young and very old, immune-compromised people, and people with chronic underlying medical conditions. Seasonal influenza viruses evolve continuously, which means that people can get infected multiple times throughout their lives. Therefore the components of seasonal influenza vaccines are reviewed frequently (currently biannually) and updated periodically to ensure continued effectiveness of the vaccines. There are three large groupings or types of seasonal influenza viruses, labeled A, B, and C. Type A influenza viruses are further divided into subtypes according to the specific variety and combinations of two proteins that occur on the surface of the virus, the hemagglutinin or “H” protein and the neuraminidase or “N” protein. Currently, influenza A(H1N1) and A(H3N2) are the circulating seasonal influenza A virus subtypes. This seasonal A(H1N1) virus is the same virus that caused the 2009 influenza pandemic, as it is now circulating seasonally. In addition, there are two type B viruses that are also circulating as seasonal influenza viruses, which are named after the areas where they were first identified, Victoria lineage and Yamagata lineage.
    [Show full text]
  • Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
    Review Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines Ekramy E. Sayedahmed 1 , Ahmed Elkashif 1, Marwa Alhashimi 1, Suryaprakash Sambhara 2,* and Suresh K. Mittal 1,* 1 Department of Comparative Pathobiology, Purdue Institute for Immunology, Inflammation and Infectious Disease, Purdue University Center for Cancer Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA; [email protected] (E.E.S.); [email protected] (A.E.); [email protected] (M.A.) 2 Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA * Correspondence: [email protected] (S.S.); [email protected] (S.K.M.) Received: 2 August 2020; Accepted: 17 September 2020; Published: 1 October 2020 Abstract: Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe.
    [Show full text]
  • Cold and Flu Fact Sheet
    Cold and Flu Fact Sheet The common cold, including chest colds, head colds, and the seasonal flu are caused by viruses that can put a damper on your holiday spirit. While Cold and Flu season can start as early as October and can last as late as May, activity peaks during Christmas time and will want to make you say Bah-Humbug! General Information Virology Clinical manifestations Cold - The common cold is a viral infection of the upper Cold - Symptoms of a common cold usually appear about respiratory tract. The most commonly implicated virus is a one to three days after exposure to a cold-causing virus. rhinovirus. Other commonly implicated viruses include Signs and symptoms typically include a runny/stuffy nose, human coronavirus, influenza viruses, and adenovirus. itchy/sore throat, cough, congestion, slight body aches and Frequently, more than one virus is present. The difficultly mild headache, sneezing, water eyes, and mild fatigue. with pathogens associated with the common cold is that some viruses are enveloped, meaning they are easy to kill Flu - Symptoms of seasonal influenza are very similar to (such as influenza) while others are non-enveloped, those of the common cold, except the flu can be meaning they are harder to kill (such as rhinovirus). This distinguished by a high fever and more severe symptoms emphasizes the importance of choosing disinfectant of the common cold. products with the ability to kill both enveloped and non- enveloped viruses. Pandemics and Outbreaks A pandemic is a global disease outbreak. It is determined Flu - Influenza (commonly known as the flu) are influenza by how the disease spreads, not by how many deaths it viruses which are enveloped, RNA viruses that make up causes.
    [Show full text]
  • Avian Influenza Importance Avian Influenza Viruses Are Highly Contagious, Extremely Variable Viruses That Are Widespread in Birds
    Avian Influenza Importance Avian influenza viruses are highly contagious, extremely variable viruses that are widespread in birds. Wild birds in aquatic habitats, particularly waterfowl and Fowl Plague, Grippe Aviaire shorebirds, are thought to be their natural reservoir hosts, but domesticated poultry can also be infected.1-9 Most of these viruses cause only mild disease in poultry, and are called low pathogenic avian influenza (LPAI) viruses. Highly pathogenic avian Last Updated: September 2014 influenza (HPAI) viruses can develop from certain LPAI viruses, usually while they are circulating in poultry flocks.10 HPAI viruses can kill up to 90-100% of the flock, and cause epidemics that may spread rapidly, devastate the poultry industry and result 2,11,12 in severe trade restrictions. In poultry, the presence of LPAI viruses capable of 11 evolving into HPAI viruses can also affect international trade. Avian influenza viruses can occasionally affect mammals, including humans, usually after close contact with infected poultry. While infections in people are often limited to conjunctivitis or mild respiratory disease, some viruses can cause severe illness. In particular, Asian lineage H5N1 HPAI viruses have caused rare but life- threatening infections, now totaling more than 650 laboratory-confirmed cases since 1997,13 while more than 400 serious illnesses were caused by an H7N9 LPAI virus in China during 2013-2014 alone.14,15 H5N1 HPAI viruses can also infect other species of mammals, in some cases fatally.12,16-35 In rare cases, avian influenza viruses can become adapted to circulate in a mammalian species, and these viruses have caused or contributed to at least three past pandemics in humans.
    [Show full text]
  • 1 Influenza at the Human-Animal Interface Summary and Assessment
    Influenza at the human-animal interface Summary and assessment, from 24 October to 9 December 2020 • New infections1: Since the previous update on 23 October 2020, one human infection with an avian influenza A(H5N1) virus, one human infection with an avian influenza A(H5N6) virus, one human infection with an avian influenza A(H9N2) virus, one human infection with an influenza A(H1N1) variant virus, and one human infection with an influenza A(H1N2) variant virus were reported.2 • Risk assessment: The overall public health risk from currently known influenza viruses at the human-animal interface has not changed, and the likelihood of sustained human-to-human transmission of these viruses remains low. Human infections with viruses of animal origin are expected at the human-animal interface wherever these viruses circulate in animals. • IHR compliance: All human infections caused by a new influenza subtype are required to be reported under the International Health Regulations (IHR, 2005).3 This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface. Avian Influenza Viruses Current situation: Avian influenza A(H5) viruses Since the last risk assessment on 23 October 2020, one new laboratory-confirmed human case of influenza A(H5N1) virus infection was reported to WHO from Lao People’s Democratic Republic (PDR) on 31 October 2020.
    [Show full text]
  • What People Who Raise Pigs Need to Know About Influenza (Flu)
    What People Who Raise Pigs Need To Know About Influenza (Flu) Introduction As someone who raises pigs, whether for show (e.g. 4-H or Future Farmers of America [FFA]) or as part of a farming operation (i.e. commercial pork producer), you may have questions about influenza (the flu) in both pigs and people. This document addresses what is known about flu viruses in pigs and people and what people in contact with pigs can do to reduce the risk of getting sick or of getting their pigs sick. Influenza Virus Infections in Pigs There are many causes of respiratory disease in pigs, including influenza. Among influenza types, only type A influenza viruses are known to infect pigs. Although pigs and people now share the H1N1 pandemic virus, other viruses circulating in swine are different from viruses circulating in people. At this time, there are three main flu A viruses that circulate in U.S. pigs: influenza A H1N1, influenza A H1N2 and influenza A H3N2. These viruses do not usually infect people and are genetically different from the H1N1 and H3N2 viruses that commonly circulate in people. When swine flu viruses are very different from the human flu viruses causing illness in people, people may have little to no immune protection against these swine viruses. Also human flu vaccines probably would not offer protection against the viruses that are found in pigs. Flu viruses commonly infect pigs and pig herds and can result in high rates of illness among pigs, but few deaths. Signs of influenza in pigs include: • Coughing (“barking”) • Breathing difficulties • Sneezing • Discharge from the nose • High fevers • Going off feed However, pigs also may become infected with flu viruses from people, and from birds.
    [Show full text]
  • Weekly Influenza Report Week 9
    Weekly Influenza Report Week 9 Report Date: Friday, March 09, 2018 The purpose of this report is to describe the spread and prevalence of influenza-like illness (ILI) in Indiana. It is meant to provide local health departments, hospital administrators, health professionals and residents with a general understanding of the burden of ILI. Data from several surveillance programs are analyzed to produce this report. Data are provisional and may change as additional information is received, reviewed and verified. For questions regarding the data presented in this report, please call the ISDH Surveillance and Investigation Division at 317-233-7125. WEEKLY OVERVIEW Influenza-like Illness - Week Ending March 3, 2018 ILI Geographic Distribution Widespread ILI Activity Code High Percent of ILI reported by sentinel outpatient providers 4.27% Percent of ILI reported by emergency department chief 3.55% complaints Percent positivity of influenza specimens tested at ISDH 70% Number of influenza-associated deaths this season 265 Number of long-term care facility outbreaks this season 104 Number of school-wide outbreaks this season 6 SENTINEL SURVEILLANCE SYSTEM Data are obtained from sentinel outpatient providers participating in the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet). Data are reported on a weekly basis for the previous Morbidity and Mortality Weekly Report (MMWR) Week by the sentinel sites and are subject to change as sites back- report or update previously submitted weekly data. Percent of ILI Reported by Type of
    [Show full text]
  • Like Illness in an Otherwise Healthy Adult Outpatient Cohort
    Original research Effects of human immunodeficiency virus status J Investig Med: first published as 10.1136/jim-2020-001694 on 23 April 2021. Downloaded from on symptom severity in influenza- like illness in an otherwise healthy adult outpatient cohort Rhonda E Colombo ,1,2,3 Christina Schofield,1,2 Stephanie A Richard,2,3 Mary Fairchok,1,2,3 Wei- Ju Chen,2,3 Patrick J Danaher,4 Tahaniyat N Lalani,2,3,5 Michelande Ridoré,2,3 Ryan C Maves,6 John C Arnold,7 Anuradha Ganesan,2,3,8 Brian Agan,2,3 Eugene V Millar,2,3 Christian Coles,2,3 Timothy H Burgess2 ► Additional supplemental ABSTRACT Significance of this study material is published online The impact of HIV on influenza- like illness (ILI) only. To view, please visit has been incompletely described in the era of the journal online (http:// dx. What is already known about this subject? doi. org/ 10. 1136/ jim- 2020- combination antiretroviral therapy, particularly in the 001694). post- H1N1 pandemic period. This analysis informs ► The relative contribution of specific on ILI in an otherwise healthy, predominantly respiratory viruses to acute respiratory For numbered affiliations see illness is likely to vary by season and end of article. outpatient cohort of adults with HIV in the USA. From September 2010 to March 2015, this multisite patient population. Correspondence to observational cohort study enrolled otherwise ► HIV has been described as a risk factor Dr Rhonda E Colombo healthy adults presenting to a participating US for both acquisition and severity of acute and Dr Christina Schofield, military medical center with ILI, a subset of whom respiratory infections in low- income and Department of Medicine, middle- income countries.
    [Show full text]
  • Influenza Viral Shedding in a Prospective Cohort of HIV-Infected and Uninfected Children and Adults in 2 Provinces of South Africa, 2012–2014
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2019 May 03. Published in final edited form as: J Infect Dis. 2018 September 08; 218(8): 1228–1237. doi:10.1093/infdis/jiy310. Influenza Viral Shedding in a Prospective Cohort of HIV-Infected and Uninfected Children and Adults in 2 Provinces of South Africa, 2012–2014 Claire von Mollendorf1,2, Orienka Hellferscee1,3, Ziyaad Valley-Omar1,6, Florette K. Treurnicht1, Sibongile Walaza1,2, Neil A. Martinson4, Limakatso Lebina4, Katlego Mothlaoleng4, Gethwana Mahlase7, Ebrahim Variava5,8, Adam L. Cohen9,10,a, Marietjie Venter11, Cheryl Cohen1,2, and Stefano Tempia9,10 1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, University of the Witwatersrand, Johannesburg 2School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 3School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 4Perinatal HIV Research Unit, Medical Research Council Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg 5School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 6Department of Pathology, Division of Medical Virology, University of Cape Town 7Pietermaritzburg Metropolitan, KwaZulu-Natal, Atlanta, Georgia 8Department of Medicine, Klerksdorp Tshepong Hospital, North West Province, Atlanta, Georgia 9Influenza Division, Centers for Disease Control and Prevention, Pretoria, Atlanta, Georgia 10Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia 11Department of Medical Virology, University of Pretoria, Pretoria, South Africa Abstract Background—Prolonged shedding of influenza viruses may be associated with increased transmissibility and resistance mutation acquisition due to therapy.
    [Show full text]
  • Culture System in Which Viruses Like Influenza, Adenovirus, Measles, Hemadsorption Type I and II, and Poliovirus Can Be Propagated
    VOL. 45, 1959 MICROBIOLOGY: H. F. MAASSAB 1035 clear if one observes that the z-coordinate on a minimal surface is a harmonic function on the surface, so that one may complete it to an analytic function z + it, and apply the above methods. THE PROPAGATION OF MULTIPLE VIRUSES IN CHICK KIDNEY CULTURES* BY HUNEIN F. MAASSAB DEPARTMENT OF EPIDEMIOLOGY, SCHOOL OF PUBLIC HEALTH, UNIVERSITY OF MICHIGAN Communicated by Thomas Francis, Jr., May 11, 1959 Introduction.-Efforts have been directed toward developing another tissue culture system in which viruses like influenza, adenovirus, measles, hemadsorption type I and II, and poliovirus can be propagated. The ability to grow all of these viruses in the same type of cells would permit a comparison of many of their biologic properties. Buthala and Mathews' have investigated the susceptibility of cultures of embryonic chick kidney cells to different animal viruses and Wright and Sagik2 followed up this work with the study of plaque formation by these viruses in the same culture system. We found that the kidney of a fully developed chick could be excised with greater ease than that of an embryonic chick, that the yield of cells was considerably higher, and that a number of laboratory passaged viruses could be propagated in the monkeys obtained. The system has also been found suitable for primary isolation of viruses. TABLE 1 "VIRAL SPECTRUM" OF THE CHICK KIDNEY SYSTEM Virvs Titer* TCID6o per ml. - Virus Passage Historyt 0 days 3 days 6 days Influenza A (A/AA/1/58) TW-CK5 1.5 4.5 5.3 B (Lee) E4F3M48ErO-CK5 2.0 3.8 4.5 C (JJ) AE43 1.8 0 0 Adenovirus HeLa cells2o Type 4 CK5 2.0 3.0 4.3 Hemadsorption Type I MK-CK5 1.8 4.5 5.3 Type I MK-CK5 2.3 4.7 5.0 Measles Chick embryo 1 .3 2.8 4.0 cells3.-CK5 Polio MK-CK5 1.0 2.7 3.8 Type I Stool specimen-CK5 1 .3 3.3 4.3 * All titers are expressed as the negative log of the dilution which will infect 50 per cent of inoculated chick kidney cultures tubes.
    [Show full text]
  • Norovirus Capsid Protein-Derived Nanoparticles and Polymers As Versatile Platforms for Antigen Presentation and Vaccine Development
    Review Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development Ming Tan 1,2,* and Xi Jiang 1,2,* 1 Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA 2 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA * Correspondence: [email protected] (M.T.); [email protected] (X.J.); Tel.: 513-636-0119 (X.J.); Tel.: 513-636-0510 (M.T.) Received: 31 July 2019; Accepted: 9 September 2019; Published: 12 September 2019 Abstract: Major viral structural proteins interact homotypically and/or heterotypically, self- assembling into polyvalent viral capsids that usually elicit strong host immune responses. By taking advantage of such intrinsic features of norovirus capsids, two subviral nanoparticles, 60-valent S60 and 24-valent P24 nanoparticles, as well as various polymers, have been generated through bioengineering norovirus capsid shell (S) and protruding (P) domains, respectively. These nanoparticles and polymers are easily produced, highly stable, and extremely immunogenic, making them ideal vaccine candidates against noroviruses. In addition, they serve as multifunctional platforms to display foreign antigens, self-assembling into chimeric nanoparticles or polymers as vaccines against different pathogens and illnesses. Several chimeric S60 and P24 nanoparticles, as well as P domain-derived polymers, carrying different foreign antigens, have been created and demonstrated to be promising vaccine candidates against corresponding pathogens in preclinical animal studies, warranting their further development into useful vaccines. Keywords: nanoparticle; vaccine platform; P particle; S particle; protein polymer; subviral particle; subunit vaccine; norovirus; rotavirus; hepatitis E virus; astrovirus 1.
    [Show full text]
  • Influenza: a Seasonal Disease
    Influenza: A seasonal disease FACTFILE Influenza: A seasonal disease nfluenza or ‘flu’ is a common viral addition, global influenza pandemics proteins that the virus needs in order disease of the upper respiratory tract have been recorded throughout history to replicate inside the infected host cell. Iin humans (in birds it is an infection and they seem to occur every 10 to 40 The genome is protected by a membrane of the gut). There are three types of years. Between 1918 and 1919 flu is envelope. Protruding from the virus influenza virus: influenza A, B and C. thought to have killed over 50 million membrane are hundreds of copies of two However, a fourth type, influenza D, people (6 times as many as died as a different varieties of viral glycoprotein has recently been discovered as a consequence of the first-world war). It spikes. Approximately 80% of the veterinary infection, particularly of was caused by an unusually pathogenic spikes are haemagglutinin (HA) and the cows. Major outbreaks of influenza are strain of influenza A virus. remaining 20% are neuraminidase (NA). associated with influenza virus type A The HA and NA surface proteins are or B. Influenza C is common but seldom What causes flu? involved in viral attachment and entry causes disease The influenza virus particle – virion to host cells as well as the release of Influenza A is commonly associated – is usually spherical, but sometimes new virions. They are also the main part with human disease. Each year, many filamentous, in shape and carries its of the virus recognised by our immune countries, including the UK, experience genetic material on eight pieces of single system as foreign, and most of the seasonal influenza epidemics that affect stranded RNA known as segments.
    [Show full text]